Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study. Issue 6 (December 2017)

• Record Type: Journal Article
• Authors: Kayıkçı, Ömür; Tekgündüz, Emre; Kaya, Ali Hakan; Göker, Hakan; Aslan, Alma; İskender, Dicle; Namdaroglu, Sinem; Tetik, Aysegul; Koçubaba, Şerife; Altuntaş, Fevzi
• Is Part Of: Transfusion and apheresis science. Volume 56:Issue 6(2017)
• Page Start: 832
• Page End: 835
• Publication Date: 2017-12
• Subjects: Autologous hematopoietic cell transplantation -- Stem cell mobilization -- G-CSF -- Biosimilars; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2017.11.016
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Biosimilar filgrastim (Leucostim ® ) was shown to be similar in terms of efficacy and safety in hematopoietic progenitor cell mobilization (HPCM) compared to originator filgrastim (Neupogen ® ) and lenograstim (Granocyte ® ) in healthy donors and chemomobilization settings. Here we report our retrospective experience with Leucostim ® (n: 43) compared to Neupogen ® (n: 71) and Granocyte ® (n: 32) in steady-state mobilization of patients presenting with Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma. The median age of patients on Leucostim ® (56) arm was significantly higher compared to patients who received Neupogen ® (50) and Granocyte ® (49) (p: 0.039). Patients who underwent HPCM with Leucostim ® received less chemotherapy lines (p: 0.026) and courses (p: 0.046) compared to others. Otherwise the study cohort was homogenous in terms of gender, primary diagnosis and various risk factors for mobilization failure. Mobilization failure was defined as failure to achieve a minimum threshold (10/μL) for peripheral blood CD34 + cell concentration to initiate leukapheresis or 0.5 × 10 6 /kg, 0.8 × 10 6 /kg and 2 × 10 6 /kg CD34 + cells in first, second and fourth days of apheresis, respectively. The study groups were similar in terms of median number of CD34 + progenitor cell yield ( × 10 6 /kg) (Neupogen ® : 6.18, Granocyte ® : 6.2 and Leucostim ® : 6.2) (p: 0.959) and median number of leukapheresis sessions (p: 0.615). The treatment arms were also similar in terms of mobilization failure (Neupogen ® 11.3% − Granocyte ® 21.9% − Leucostim ® 16.3%; p: 0.366). No patient experienced any severe adverse effect during HPCM. Leucostim ® is equally effective and safe in HPCM compared to originator G-CSF (Neupogen ® ) and lenograstim (Granocyte ® ) in steady-state HPCM setting.